HHS: Moving is Good Medicine for Adults aged 65 Years and Older
Less than 15% of US adults in the population aged 65 years and older achieve recommended weekly levels of physical activity and strengthening, according to HHS.
Health Inequities in Persons with Obesity & Type 2 Diabetes Exacerbated During COVID-19 Pandemic
Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.
Studies of Novel, Highly Effective Antiobesity Medications Headline 83rd ADA Scientific Sessions
Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
Your daily dose of clinical news you may have missed.
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Daily Dose: Novel Drug Therapy for Obesity Shown Effective Up to 46 Weeks
Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors
ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.
Daily Dose: Tirzepatide Leads to 15% Weight Loss in Adults with Obesity, T2D
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
Survodutide, Novel Dual GLP-1/Glucagon Agonist, Achieves ~19% Weight Loss in People with Overweight, Obesity
ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
Friday's 5 Quotes for Primary Care
SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.
Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Obesity & Type 2 Diabetes: Early Intervention Critical in Reducing Risk for Complications
Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.
Daily Dose: Healthy Lifestyle & Risk of CVD Among Postmenopausal Women With Normal BMI
For Unknown Causes of Kidney Disease, Genetic Testing Holds Promise
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
